Medical Content Writer

November 19, 2025

Ayvakit (Avapritinib) is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, advanced systemic mastocytosis (AdvSM) which includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), mast cell leukemia (MCL) and indolent systemic mastocytosis (ISM). It is a selective tyrosine kinase inhibitor targeting KIT D816V, PDGFRA D842V, and multiple KIT mutations with potent IC50s (<25 nM). It inhibits autophosphorylation and cell proliferation in KIT/PDGFRA mutant cell lines and shows anti-tumor activity in xenograft models, including imatinib-resistant GIST and mastocytoma. It offers a targeted treatment option for advanced systemic mastocytosis and gastrointestinal stromal tumors (GIST). With strong central nervous system penetration and selectivity, avapritinib demonstrates high efficacy and durable responses. Its unique mechanism supports use in mutation-driven cancers with limited treatment options. Avapritinib is not recommended for the treatment of patients with AdvSM or ISM with platelet counts of less than 50 X 109/L. The common side effects of avapritinib use include intracranial hemorrhage, cognitive effects and photosensitivity. There is no data on the presence of avapritinib or its metabolites in human milk or effects on breastfed children or milk production. Post partum women are advised not to breastfeed during treatment or two weeks following the final dose. Advise effective contraception during treatment and for 6 weeks post final dose due to potential fetal harm. Avapritinib may impair male and female fertility. Safety and effectiveness in pediatric patients not established. No overall differences in safety or effectiveness in patients above 65 years of age, compared to younger patients. No dose adjustment required for patients with mild or moderate renal or hepatic impairment. Recommended dose not established for patients with severe renal impairment. A lower starting dose for patients with severe hepatic impairment is advised.

Pricing and Availability

Avapritinib is not approved for commercial sale in India and is therefore unavailable through regular pharmacies or local distributors. Since it is a prescription-only therapy, pricing details for those looking to import avapritinib in India are provided upon request, after submitting valid medical documents and a doctor’s prescription. For the latest pricing information and procurement support, patients or caregivers should contact our team directly. The price of avapritinib in India may vary depending on several factors, including supplier source, market conditions, regulatory requirements, and international availability. Additional elements such as shipping costs, documentation fees, origin country, and currency exchange rates may also influence the final price. Fluctuations in GST or local taxes, as well as adjustments in manufacturer pricing policies, can further affect total cost. We facilitate patient access to avapritinib in India under the Named Patient Supply (NPS) program, ensuring full legal and regulatory compliance. Our dedicated support team oversees the process from document verification to final delivery, ensuring safety and transparency at each stage.

Access Pathway

Since avapritinib is not commercially licensed in India, it can only be accessed through the Named Patient Import Program (NPIP). Through this route, we assist patients in obtaining unregistered medicines like avapritinib under the NPS framework, in accordance with applicable import regulations. Avapritinib is available as 25 mg, 50 mg, 100 mg, 200 mg and 300 mg tablets, in bottles of 30 tablets.

Import Process

Submission of Request: Patients or caregivers initiate the process by submitting a formal request, along with treatment details and a valid prescription.
Form 12A Application: An application must be submitted in Form 12A, accompanied by a prescription issued by a Registered Medical Practitioner (RMP).
Document Verification: All submitted medical and identification documents are reviewed to confirm eligibility for import under the personal medical use category.
Regulatory Authorization: Upon approval from the Drugs Controller General (India), the import procedure is initiated as per the approved prescription.
Global Sourcing: Our procurement team collaborates with authorized international suppliers to source the medicine at the most competitive rate, ensuring product authenticity and compliance.
Delivery and Fulfilment: Following regulatory approval, logistics and customs procedures are coordinated to ensure secure, compliant, and timely delivery to the patient’s address in India.

Required Documentation

To facilitate import of avapritinib in India, patients are required to provide:

A valid doctor’s prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and supporting laboratory reports (preferably within the past three months).
Government-issued identification and proof of residence of the patient.
Import permit (if applicable).

Orders are finalized only upon receipt of all required documents and verification of medical eligibility. Once the import permit is approved, the licensed supplier arranges shipment of avapritinib to India from approved international sources such as the United States, Canada, Europe, or Australia. We ensure that every import is conducted safely, ethically, and in full regulatory compliance. Our organization provides nationwide delivery through verified suppliers, guaranteeing product authenticity and complete transparency in pricing and process. All prescriptions are reviewed and dispensed by registered pharmacists prior to delivery. For detailed information or pricing, patients can contact 247QualityMeds.com directly. Our team is available to assist with all inquiries and guidance.

by Dr. Banisetti Sravya

November 13, 2025

Kineret-Anakinra-in-India-Uses-Administration-Where-to-Buy-2-1280x800.jpg

Kineret is a prescription medication used to treat medical conditions like Rheumatoid Arthritis (RA) in adults, Neonatal-Onset Multisystem Inflammatory Disease (NOMID) in newborns, and in cases of decreased Interleukin-1 Receptor Antagonist (Blocks interleukin-1 from activating inflammation in the body).

How does Kineret (Anakinra) work?

Anakinra is the key component in the Kineret, which works as an immunosuppressive agent (that suppresses the immune system in the body). This replicates the interleukin 1 (IL-1) receptor antagonist in humans, which stops the receptors for signal molecules in the body known as interleukin 1. When the signal molecules are produced in higher quantities, it leads to inflammation of joints. By uniting the receptors that IL-1 usually attaches itself to, Anakinra obstructs IL-1 activity, resulting in relieving the symptoms of RA.

Indications

Kineret is indicated in: 1) Rheumatoid Arthritis: Reduction in signs and symptoms and slowing the progression of the structural damage in moderately to severely active Rheumatoid arthritis (RA), in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). 2) Cryopyrin-Associated Periodic Syndromes (episodes of uncontrolled inflammation) Treatment of Neonatal-onset Multisystem Inflammatory Disease (NOMID) 3) Deficiency of Interleukin-1 Receptor Antagonist (Blocks interleukin-1 from activating inflammation in the body)

Side-effects

Rheumatoid Arthritis (RA) The common side effects are injection site reaction, worsening of Rheumatoid Arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia (Joint pain), flu-like symptoms, and abdominal pain. NOMID: During the initial 6 months of treatment, injection site reactions, headache, vomiting, arthralgia, pyrexia (high body temperature), and nasopharyngitis are common side effects. DIRA: Upper respiratory tract infections, rash, pyrexia (high body temperature), influenza-like illness, and gastroenteritis are common side effects in patients with DIRA.

Dosage and administration

Rheumatoid Arthritis (RA)

The recommended dose of Kineret for patients suffering from RA is 100mg per day, which is to be administered by subcutaneous injection every day. This dosage is maintained around the same time daily.
Physicians should consider a dose of 100mg of Kineret administrated everyday for RA patients who have severe renal insufficiency or end-stage renal disease (defined as a creatinine clearance less than 30mL/min, as estimated from serum creatinine levels).

NOMID

The recommended starting dose of Kineret is 1-2mg/kg everyday for patients suffering from NOMID.
Physicians should consider a dose of 1-2mg/kg of Kineret every other day for NOMID patients who have severe renal insufficiency or end stage renal disease (defined as a creatinine clearance less than 30mL/min, as estimated from serum creatinine levels).

DIRA

The recommended initial dose is 1-2mg/kg daily for patients with DIRA. The dose can be individually adjusted to a maximum of 8mg/kg daily to control active inflammation.
Physicians should consider administration of the Kineret dose every other day for patients with DIRA who have several renal insufficiencies or end-stage renal disease(defined as a creatinine clearance less than 30mL/min, as estimated from serum creatinine levels).

Where to buy Kineret in India?

Since Kineret is not registered in India, it’s not possible to get access in India except through legal means. However, we are here to help you in this process to import anakinra in India safely and on time. The anakinra price in India is completely based on the parameters like its distribution status, supply chain management, transportation, and tariffs, but we can assure you that we offer it at a very competitive price. The packaging comes as a single-use prefilled syringe designed for subcutaneous injections. The dosage of the injection is 100mg/0.67mL solution. We will walk you through this systematic protocol to import anakinra. 1) Placing an order request You can request by notifying us regarding Kineret on our website portal. Make sure to send the patient’s prescriptions with the past health record. 2) Report submission of the Form Complete the submission of Form No. 12A by attaching the patient’s prescription from a Registered Medical Practitioner (RMP). 3) Validation and cross-border importation We check all the related documents and personal identification proofs to ensure the fulfillment of the eligibility criteria. And, when the permission from the Drugs Controller General (India) to import is obtained, our team makes the next move. 4) Vendor selection Our professionals search for the global vendors and lock in your order at the best affordable value only after understanding their credibility. 5) Order fulfilment All further processes, like transportation, transit, and doorstep delivery, are completely taken care of by our company staff.

Conclusion

Kineret availability often poses challenges; that’s where 24/7QualityMeds comes in. Our experienced team handles the complete process seamlessly. Get in touch with us, and we will handle the rest. Visit our website and explore more for updates.

by Dr. Banisetti Sravya

November 12, 2025

Columvi is a drug used for cancer patients suffering from diffuse large B-cell lymphoma DLBCL), a cancer involving a kind of white blood cell. This DLBCL comes under the subtype called Non-Hodgkin’s Lymphoma (NHL). There are about 30-40% cases of NHL cases estimated worldwide. According to the GLOBOCAN 2022 data, there are approximately 1,50,000 to 2,20,000 new cases of DLBCL found every year among 5,45,000 new cases of NHL, affecting people globally.

Mechanism of action

Glofitamab is an active ingredient in Columvi, which is an antibody (a type of protein) manufactured in such a way to identify and bind to CD20, a type of protein that resides on the surface of healthy T cells (a type of white blood cell that takes part in the body’s natural defence and kills cancer cells). When the binding of both CD20 and CD3 occurs, the combination effects of both cancer cells and T-cells cause the cancer cells to die.

Indications

Columvi is a bispecific CD20-directed CD3 T-cell engager (unites the two types of immune cells, which are CD20 and CD3) is indicated for adults with relapse or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma after two or more after two or more lines of systemic therapy (therapy that affects the entire body).

Side effects

The most common side effects are listed below:

cytokine release syndrome (the body releases too many inflammation-causing chemicals)
musculoskeletal pain
Rash
Fatigue.

Other laboratory abnormalities include:

A decrease in lymphocyte count, phosphate, and neutrophil count, fibrinogen, and
An increase in uric acid.

Major Safety concerns and monitoring

Neurological Toxicity:

Some people may feel sleepy or have difficulty speaking or writing. Monitor the patient for long-term symptoms.

Infections:

Columvi can make the immune system weak. Monitor the patients for serious infections.

Tumor flare:

Monitor the patients for tumor flare after the cancer cells die.

Access Checklist:

The Glofitamab price in India varies from time to time since it is not registered in India, so we import Glofitamab from other countries through official legitimate channels at fair prices. We can help you buy Columvi in India when you get a prescription from certified doctors regarding your medical condition. We provide the medicine in the form of injection as 2.5mg/2.5mL or 10mg/10mL (1mg/1mL) in a single vial according to the dosage of the patient. Our specialised team guides you with the Glofitamab import process, as mentioned below:

Request for Columvi availability: We kindly request you to send a notification request for Columvi availability in India

Form no. 12: We assist in the submission of mandatory Form No. 12. Besides this requires submission of a proper prescription approved by a Registered Medical Practitioner (RMP).

Cross-checking of regulatory documents: We check all the prescriptions along with the patient’s medical documents to ensure eligibility for the legal Glofitamab import process.

Import the drugs: Importation is only possible after permission from higher authorities, such as the Drugs Controller General (India).

Navigating and delivery of the medicine: Our expert team navigates the location of Columvi availability with the suppliers who are internationally certified, checks their authenticity, and finalises it. We check the safe delivery of the medicine along with the warehouse section, shipment and finally till the door delivery of the medicine to the patient.

Conclusion

Do you want to make your journey through the import process of the rare medicines easy and transparent? 24/7QualityMeds takes utmost care of every step, be it documentation or delivery, without any confusion. We aim for your safety and satisfaction. Reach out to us today for your tailored medical needs.

by Dr. Banisetti Sravya

November 10, 2025

Blincyto is a targeted immunotherapy approved worldwide to treat certain B-cell Acute Lymphoblastic Leukemia (ALL). The incidence of this disease is approximately 1-2 out of 1,00,000 persons. The adult patients suffering from ALL range from 7.3% to 57.8% whereas ALL in children accounts for 19% of childhood cancers in India by 2021. Patients looking for complete procurement guidance can also read our detailed guide on How to Buy Blinatumomab (Blincyto) in India Safely.

Mechanism of action

Blincyto works by the concept of BiTE (Bispecific T-Cell Engager) therapy, in which CD19 surface antigens on B cells are targeted. This enables tracking and attacking the malignant cells by engaging T cells (a type of white blood cell that functions in destroying the cells considered enemies). When the T cells are brought in proximity to the cancer cells, these T cells release toxins and induce cancer cell death (apoptosis). Currently, the BiTE therapy is being investigated for its usage in different types of cancers to benefit patients on a larger scale.

Indications

Blincyto is indicated in the treatment of adults and children aged one month and older with:

CD19-positive B-cell precursor (immature B cell in bone marrow that shows the CD19 marker on its surface) Acute Lymphoblastic Leukaemia (ALL) in first or second complete recovery, along with Minimal Residual Disease (MRD), either greater than or equal to 0.1%.
CD19-positive B-cell precursor Acute Lymphoblastic Leukaemia (ALL) recurrence or refractory type.
CD19-positive B-cell Philadelphia chromosome-negative B-cell precursor Acute Lymphoblastic Leukaemia (ALL) in the consolidation phase of multiphase chemotherapy.

Side-effects

The most common side effects in patients taking Blincyto are high temperature, infusion-related reactions, headache, infection, musculoskeletal pain, low neutrophil count, low Red Blood Cell count, low thrombocyte count, and diarrhoea.

Warnings and precautions

Monitor the patients for infections
Monitor if the patient shows the symptoms of Pancreatitis
Follow the instructions as given by the manufacturer for preparation (including admixing) and administration
Avoid operating heavy or potentially dangerous machinery
Make sure to use preservative-free saline for children weighing less than 22 kg.

Ordering guide

Blincyto is available as an injection form of 35mcg in a single-dose vial. The blinatumomab availability in India is not authorized , but we help patients to import it in case of their critical need when the doctor advises the patient to buy blincyto India or to import it. We have simplified the ordering process in a step-by-step manner.

1) Order for a Blincyto medicine

You can request a Blincyto on the website and send all the medical history of the patient with a valid prescription for a diagnosed condition.

2) Submission of mandatory Form No. 12

Our team guides you in filing the Form No. 12. Submit a valid prescription from a Registered Medical Practitioner (RMD).

3) Confirmation of the documents

We confirm the documents by verifying the prescription given by a registered healthcare worker, and also the personal ID documents from the patient.

4) Blincyto import

Once the government authorities grant permission from the Drugs Controller General (India), we commence with the importation process.

5) Genuineness of the medicine

Our assigned team makes a note of all the worldwide suppliers and makes the best economic choice.

6) Packaging and distribution of the medicine

Our transport team ensures packaging, labeling, and quality and delivery of the product within the stipulated time. The blinatumomab price in India is not constant, but we guarantee to provide the medicines at a cost-effective price meeting the international pharmaceutical norms, since it involves legal import channels. Trust 24/7QualityMeds to access the medicines to patients in medical need with absolute transparency. Our dedicated team is here to manage everything, right from the import to delivery, so that you focus on what matters the most. For detailed information about Blincyto price in India and legal import process, read: Blinatumomab (Blincyto) in India: Pricing, Import Steps & Access Information

by Dr. Banisetti Sravya

November 5, 2025

Eculizumab is indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, anti-AchR antibody-positive generalised myasthenia gravis, and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder. It is administered as an intravenous infusion. It is a recombinant humanised monoclonal IgG antibody (IgG2/4𝛋) produced by murine myeloma cell culture. It specifically binds to C5, a complement protein, inhibiting cleavage to C5a and C5b, which ultimately leads to C5b-9. It inhibits the intravascular hemolysis caused by the terminal product in patients with complement-mediated thrombotic microangiopathy in patients with aHUS. The precise mechanism in gMG and NMOSD is unknown, but it is presumed to involve inhibition of antibody-induced complement deposition. There are certain risks in pregnant patients suffering from PNH and aHUS being administered Soliris. Published data does not report the presence of eculizumab in human milk, although maternal IgG may be present. No data on the effect on breastfed children or on milk production. Patients’ condition and potential effect on breastfed children need to be considered before deciding on treatment. Safety and effectiveness in pediatric patients have not been established – no apparent age-related differences in geriatric patients. Soliris or eculizumab is contraindicated in patients with unresolved Neisseria meningitidis infection and those who are not currently vaccinated against the same infection, unless the risk of delaying the eculizumab treatment outweighs the risks of developing meningococcal infection. Adverse reactions of the treatment include serious meningococcal infections, infusion reactions as well as any other systemic infection. Specific adverse reactions include headache, nasopharyngitis, back pain, nausea, diarrhoea, urinary and respiratory tract infections, peripheral edema, abdominal pain, musculoskeletal pain, among others.

Pricing and Availability

Eculizumab is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels. As this is a prescription-only treatment, the price quotation for eculizumab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly. The cost of eculizumab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements. Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients to import eculizumab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step—from verifying documents to final delivery.

Access

As Eculizumab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines such as Eculizumab by helping procure them under the Named Patient Supply (NPS) route. Eculizumab injection is available as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton.

Import Process

Submit a request for your medicine Patients or caregivers can share their prescription and treatment details to initiate the request.
Apply through Form 12A An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
Document verification All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
Import permission Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
Sourcing the medicine Our sourcing team coordinates with authorized international suppliers to find the best available price in India, ensuring product authenticity before finalizing the purchase.
Medicine delivery After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of Eculizumab to India, patients must provide:

A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
Government-issued ID and proof of residence of the patient.
Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of eculizumab from approved international sources such as the USA, Canada, Europe, or Australia. Through this process, patients can import eculizumab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. Any patients seeking comprehensive information about this medication, including availability and guidance, are encouraged to reach out. For detailed support or pricing assistance, please visit 247qualitymeds.com.

by Dr. Banisetti Sravya

November 4, 2025

Strensiq or asfotase alfa is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). HPP is caused by a deficiency in TNSALP enzyme activity, leading to elevations in several substrates, like inorganic pyrophosphate (PPi). TNSALP is a metalloenzyme that catalyzes the hydrolysis of phosphomonoesters with the release of inorganic phosphate and alcohol. Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix, which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon asfotase alfa treatment reduces the enzyme substrate levels. There are no available data on asfotase alfa use in pregnant women to inform a drug-associated risk, presence of asfotase alfa in human milk, the effects on the breastfed infant, or the effects on milk production. Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for asfotase alfa and any potential adverse effects on the breastfed infant from asfotase alfa or from the underlying maternal condition. Safety and effectiveness of asfotase alfa for the treatment of perinatal/infantile- and juvenile-onset HPP have been established in pediatric patients. There is no information available to determine whether geriatric patients differ in terms of adverse reactions and response, as compared to younger patients. Asfotase alfa is for subcutaneous injection only. The following are the most adverse reactions reported in patients undergoing treatment (incidence rates being gretaer than 10%) with asfotase alfa: hypersensitivity reactions, lipodystrophy, ectopic calcifications, and possible immune-mediated clinical effects

Pricing and Availability

Asfotase alfa is not currently registered in India and is therefore not available through regular pharmacies or standard distribution channels. As this is a prescription-only medication, a price quotation for asfotase alfa is shared only after reviewing valid medical documents and a doctor’s prescription. For the most up-to-date pricing and supply details, patients may contact our support team. The price of asfotase alfa in India may differ based on factors such as market demand, supplier access, import regulations, and availability from international manufacturers. The total cost may also depend on shipping charges, origin country, documentation fees, and currency exchange rates. Pricing may be affected by local taxes (GST) and any revisions in company or distributor pricing policies. We assist patients in India with the safe and lawful access through import asfotase alfa through the Named Patient Supply (NPS) program, ensuring compliance with all import regulations. Our services include document verification, import coordination, and doorstep delivery of the medicine.

Patient Access

Since asfotase alfa is not approved for commercial sale in India, it can be obtained only through the Named Patient Import Program (NPIP). We help patients obtain unregistered medicines under the NPS route, maintaining full adherence to applicable legal and regulatory standards. Strensiq or asfotase alfa is available as injection: 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or 80 mg/0.8 mL solution in single-dose vials with each carton containing 1 or 12 vials.

Import Procedure

Medicine Request Submission: Patients or caregivers can begin by submitting a request, along with their doctor’s prescription and treatment information.
Filing Form 12A: A completed Form 12A and a valid prescription from a Registered Medical Practitioner (RMP) must be submitted.
Verification Process: All documents are carefully reviewed to confirm the patient’s eligibility to import the medicine for personal medical use.
Regulatory Approval: Once approval is received from the Drugs Controller General (India), the import procedure is initiated in accordance with the approved prescription.
Medicine Procurement: Our procurement specialists connect with licensed international suppliers to source the medicine at the best possible rate while ensuring authenticity and quality.
Product Delivery: Following approval and shipment, logistics are handled to ensure timely, safe, and compliant delivery of the medicine to the patient’s address in India.

Documents Required

To import asfotase alfa into India, patients must provide the following:

A valid prescription indicating the medicine name, dosage, duration, and diagnosis.
Recent medical history and diagnostic reports (preferably from the last three months).
Government-issued ID proof and proof of residence.
Import permit (if required).

Orders are confirmed only after the submission and verification of all necessary documents. Once the import authorization is granted, shipment of asfotase alfa is arranged by a licensed global supplier typically from the USA, Canada, Europe, or Australia. This process ensures that patients in India can legally and securely access and buy asfotase alfa in India. We coordinate with reliable international sources, maintain pricing transparency, and ensure all deliveries are pharmacist-verified and fully compliant with import regulations. For the best pricing, authentic sourcing, and priority assistance, connect with 247QualityMeds.com today. Our team ensures a safe and easy buying process.

by Dr. Banisetti Sravya

November 3, 2025

Mirvetuximab soravtansine-gynx for the treatment of adult patients with FRα–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test. Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC) where the monoclonal antibody is a chimeric IgG1 that targets folate receptor alpha (FRα). Th antibody is linked to a small molecule, DM4 (also known as soravtansine or ravtansine), a microtubule inhibitor by a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death, and diffuse to nearby cells causing further cell death. FRα is a receptor that is overexpressen on the surface epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and non-small-cell lung cancers. The most common adverse reactions include vision impairment, pneumonitis, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin. The cytotoxic and gentoxic component DM4 can be toxic to actively dividing cells, suggesting its potential to cause embryotoxicity and teratogenicity. Advise patients of potential risk to fetus. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose. Advise females to use effective contraception during treatment and for 7 months after the last dose. Safety and effectiveness of mirvetuximab have not been established in pediatric patients. No clinically meaningful differences in efficacy or safety were observed in geriatric patients compared to younger patients. No dosage adjustment of mirvetuximab is recommended for patients with mild to moderate renal or mild hepatic impairment. The effect of severe renal impairment or end-stage renal disease on mirvetuximab is unknown. Avoid use of mirvetuximab in patients with moderate or severe hepatic impairment.

Pricing and Availability

Mirvetuximab Soravtansine (Elahere) is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels. As this is a prescription-only treatment, the price quotation for mirvetuximab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly. The cost of mirvetuximab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements. Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients in importing mirvetuximab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step-from verifying documents to final delivery.

Access

As mirvetuximab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines by helping procure them under the Named Patient Supply (NPS) route. Each mirvetuximab soravtansine-gynx injection carton contains one single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of clear to slightly opalescent, colorless sterile solution.

Import Process

Submit a request for your medicine Patients or caregivers can share their prescription and treatment details to initiate the request.
Apply through Form 12A An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
Document verification All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
Import permission Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
Sourcing the medicine Our sourcing team coordinates with authorized international suppliers to find the best available price of mirvetuximab soravtansine in India, ensuring product authenticity before finalizing the purchase.
Medicine delivery After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of mirvetuximab to India, patients must provide:

A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
Government-issued ID and proof of residence of the patient.
Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of mirvetuximab from approved international sources such as the USA, Canada, Europe, or Australia. Through this process, patients can import mirvetuximab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. For pricing details or to request assistance in accessing mirvetuximab, visit 24/7QualityMeds.com.

by Dr. Banisetti Sravya

November 1, 2025

Foscavir is the brand name for foscarnet sodium. Foscarnet exerts its antiviral activity by a selectively inhibiting the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. It does not require activation by thymidine kinase or other kinases. Foscarnet is indicated for the treatment of:

CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). The combination of foscarnet and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. Safety and efficacy of foscavir have not been established for treatment of other CMV infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal CMV disease; or nonimmunocompromised individuals.
Acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. Safety and efficacy of foscarnet have not been established for treatment of other HSV infections (e.g., retinitis, encephalitis); congenital or neonatal HSV disease; or HSV in nonimmunocompromised individuals.

Adverse reactions of this medicine primarily include renal impairment, mineral and electrolyte abnormalities, seizures, hypersensitivity, QT prolongation. Insufficient well-controlled studies of foscavir is not done in pregnant women. There is potential for serious adverse events in nursing infants, and hence a decision should be made considering the importance of the drug to the mother. The safety and effectiveness of foscavir in pediatric patients have not been established. Since deposition in human bone has also been shown to occur, it is likely that it does so to a greater degree in developing bone in pediatric patients. No studies regarding efficacy or safety of foscavir in geriatric patients, however consistent patterns in adverse reactions seen across all age groups. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are at higher chance of having impaired renal function, care should be taken in dose selection, with monitoring of renal function.

Pricing and availability:

Foscarnet is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for Foscavir is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of foscarnet in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy foscarnet India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As foscarnet is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like foscarnet in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Foscavir or foscarnet (foscarnet sodium) injection, 24 mg/mL, for intravenous infusion, is supplied in 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) as 250 mL bottles, or in cases of 10.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best foscarnet price in India, thus making it convenient to easily import foscarnet in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Foscavir from the USA, Canada, Europe, or Australia etc.

With these steps, patients can import Foscarnet in India safely and legally. We ensure availability across major Indian cities and source only from verified international suppliers to maintain product authenticity and quality. Pricing is fully transparent, and all prescriptions are verified by registered pharmacists before delivery. For assistance with pricing, documentation, or procurement, patients may contact 24/7Qualitymeds for reliable support and seamless access.

by Dr. Banisetti Sravya

October 30, 2025

Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) witj the KRAS-G12C mutation in adults who have received at least one prior systemic therapy. It is additionally approved in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluorouracil-, oxaliplatin– and irinotecan-based chemotherapy. The usual pathway consists of GTP binding to KRAS, aloowing downstream signalling through MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib, being a KRASG12C inhibitor, binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non-small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors. This enables blocking and KRAS signaling, inhibited cell growth, and promoted apoptosis specifically in KRAS G12C tumor cell lines. This product has inhibited KRASG12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib treatment led to tumor regressions and prolonged survival, and was associated with anti-tumor immunity in KRAS G12C models. There are no available data on Sotorasib use in pregnant women. Because of the potential for serious adverse reactions in breastfed children, women are advised not to breastfeed during treatment with Lumakras and for 1 week after the final dose. The safety and effectiveness of this product have not been established in pediatric patients. No overall differences in safety or effectiveness were observed between older patients and younger patients. No dosage modification is recommended in patients with mild to moderate hepatic impairment (Child Pugh A or B). The effect of severe hepatic impairment (Child-Pugh C) on the safety of LUMAKRAS is unknown. Monitor for sotorasib adverse reactions in patients with hepatic impairment more frequently since these patients may be at increased risk for adverse reactions including hepatotoxici

Pricing and availability:

Sotorasib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for sotorasib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of sotorasib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy sotorasib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As sotorasib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like sotorasib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Sotorasib or Lumakras is available as 320 mg tablets in carton containing one bottle of 90 tablets with child-resistant closure and as 120 mg tablets in carton containing two bottles of 120 tablets or one bottle of 240 tablets with child-resistant closure,

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best sotorasib price in India, thus making it convenient to easily access Lumakras in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lumakras from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import sotorasib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients. If you are exploring reliable options to buy Sotorasib (Lumakras) in India, expert assistance is available. For accurate pricing, availability updates, and end-to-end support with the import process, you may reach out to 24/7QualityMeds. Their team helps ensure compliant sourcing and smooth delivery so patients can access this essential therapy with confidence.

by Dr. Banisetti Sravya

October 29, 2025

Mitotane is indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane or Lysodren is an adrenal cytotoxic agent which can cause adrenal inhibition, apparently without cellular destruction. The exact biochemical mechanism of action is unknown. Available data suggest that the drug modifies the peripheral metabolism of steroids as well as suppresses the adrenal cortex. It ultimately leads to reduced production of adrenal corticosteroids and aids in accumulation of free cholesterol toxic to adrenal cells. Adverse reactions include gastrointestinal disturbances like anorexia, nausea or vomiting, and diarrhea; central nervous system side effects, primarily depression as manifested by lethargy and somnolence, dizziness or vertigo; skin toxicity, et cetera. Infrequently occurring side effects involve the eye, the genitourinary, cardiovascular system; and generalized aching, hyperpyrexia, and lowered protein bound iodine. Mitotane or Lysodren is usually present in breast- milk. Hence, women are advised not to breastfeed during treatment. Safety and effectiveness in pediatric and geriatric patients has not been established sufficiently. In few clinical studies performed with geriatric patients, no significant differences in adverse reaction occurrence. However, dose adjustments are required in consideration with the co-occurence of hepatic, renal, cardiac impairment as well as any other drug or treatment being used.

Pricing and availability:

Mitotane is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for mitotane is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of mitotane in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy mitotane (Lysodren) in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As mitotane is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Mitotane or Lysodren is available as 500 mg tablets, 100 in each bottle.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best mitotane price in India, thus making it convenient to easily import mitotane in India and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lysodren from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import Mitotane in India safely and legally. We source only from verified international suppliers to ensure authenticity and make the medicine available across major Indian cities. Every order is handled with 100% transparency, and Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

For guidance on pricing, availability, and compliant import support for Mitotane, you can connect with 24/7QualityMeds for seamless assistance.

by Dr. Banisetti Sravya

October 28, 2025

Braftovi or encorafenib is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in to treat (a) Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with Mektovi (binimetinib), encorafenib is used to treat adults with melanoma or NSCLC that has a BRAF mutation. (b) Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer. The approval for this combination was based on response of the tumour and its duration. Ongoing studies are evaluating the clinical benefit of this regimen. Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment. Encorafenib is advised against for the treatment of people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no BRAF mutation), due to insufficient studies. Your healthcare provider will perform a test to confirm if encorafenib or the combination with binimetinib is appropriate for your condition. Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed better anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy. New primary malignancies, hemorrhage, uveitis and QT prolongation are the common side effects of encorafenib treatment. Breastfeeding is not recommended during treatment and for 2 weeks after. Encorafenib may impact and impair male fertility and reduce any effectiveness of hormonal contraceptives. Therefore, non-hormonal contraception is advised. Effective contraception used during and for 2 weeks after therapy. In clinical trials, no significant effect of the product’s safety or effectiveness were seen in elderly patients. However, it is not approved for pediatric use. No dose adjustment is needed for mild to moderate renal or hepatic impairment, and use in severe impairment lacks dosing recommendations.

Pricing and availability:

Encorafenib (Braftovi) is a targeted therapy designed for adults with melanoma, NSCLC, and colorectal cancer with a BRAF mutation that have spread or cannot be surgically removed. It aids in improving tumor response and the duration of benefit. When used in combination with binimetinib or cetuximab-based regimens, it offers a powerful, personalized treatment. It is not suitable for cancers without the BRAF mutation. However, encorafenib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for encorafenib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of encorafenib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy encorafenib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As encorafenib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Braftovi or encorafenib is supplied as 75 mg capsules available in cartons containing two bottles of 90 capsules each and cartons containing two bottles of 60 capsules each.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best encorafenib price in India, thus making it convenient to easily import encorafenib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Braftovi from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import encorafenib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Accessing Encorafenib (Braftovi) in India can be made seamless and compliant through the Named Patient Supply (NPS) Program. With proper guidance, patients can obtain this essential therapy safely and legally under the supervision of qualified healthcare professionals.

At 24/7 QualityMeds, we assist patients and caregivers through every stage—from documentation and regulatory approvals to sourcing from verified international suppliers. Our focus is on ensuring genuine medicines, transparent pricing, and reliable delivery across India. For the most updated details on Encorafenib pricing, availability, and import assistance in India, please contact our expert support team.

by Dr. Banisetti Sravya

October 25, 2025

Tukysa is a HER2-directed tyrosine kinase inhibitor approved in combination therapy that has demonstrated a significant overall survival benefit in patients with HER2-positive metastatic breast cancer—including those with brain metastases. Its ability to cross the blood-brain barrier and maintain efficacy makes it a critical advancement in treatment of HER2+ disease. Its favorable tolerability profile, and ability to be used post multiple HER2-targeted therapies make it a valuable option in the treatment landscape for HER2-positive metastatic breast cancer. This product manufactured by Seagen (Seattle Genetics) is a HER2-directed kinase inhibitor, meaning it blocks HER2 and HER3 phosphorylation in vitro, inhibiting downstream MAPK and AKT signaling, and reducing cell proliferation. It has shown anti-tumor activity in HER2-expressing cells. In vivo, tucatinib inhibited HER2-positive tumor growth. When combined with trastuzumab, tucatinib demonstrated enhanced anti-tumor effects in both in vitro and in vivo models compared to either agent alone. Recommended dosage is 300 mg, orally, twice daily with or without food; and for patients with severe hepatic impairment is 200 mg orally twice daily. Some of the clinically significant adverse reactions include diarrhea, embryo fetal toxicity and hepatotoxicity.

Pricing and availability:

Tucatinib (Tukysa) is prescribed for patients with HER2- positive metastatic breast cancer. However, tucatinib is not registered in India and is not readily available through local pharmacies or standard distribution networks. Since this is a prescription-only therapy, the price quotation for tucatinib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. The price of tucatinib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly. Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies. We help patients buy tucatinib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As tucatinib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like tucatinib in India by procuring medicines for patients under the Named Patient Supply (NPS) route. Tukysa or tucatinib is supplied as 50 mg or 150 mg tablets with 60 counts in each of 75 cc bottles or 150 mg tablets as 120 counts in each of 150 cc bottles.

Import process:

Request submission for your medicine Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A) Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, thus making it convenient to easily import tucatinib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Tukysa from the USA, Canada, Europe, or Australia, etc. With these steps, patients can import tucatinib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Newer Posts

Older Posts